At Coho Biologics we specialize in RNA and protein biological testing, providing rapid testing solutions for the biotechnology and pharmaceutical industry.

About Us

Our mission is to empower researchers and developers with reliable, accurate, and high-quality analytical data, enabling the safe and effective advancement of new therapeutic candidates. Whether working with RNA-based treatments, monoclonal antibodies, protein therapeutics, and vaccine antigens, we are committed to supporting our clients during the development process, from preclinical research to early clinical trials.

Our team is composed of experienced biotechnology researchers with deep expertise in molecular biology, biochemistry, and analytical sciences. With decades of combined experience in the biotech industry, our scientists are uniquely equipped to address the complex challenges of product development. We bring a passion for innovation and a rigorous approach to scientific problem-solving, ensuring that our clients receive the most precise and actionable results. We pride ourselves on maintaining high standards of quality and compliance. Operating under FDA regulatory guidelines, our laboratory adheres to cGMP and GLP standards, ensuring that all testing is conducted with the utmost accuracy and integrity. Our facilities are equipped with advanced technologies to perform a wide range of services, including storage, stability studies, potency assays, impurity characterization, and method development. At Coho Biologics, we understand the critical importance of your work in improving human health. Our mission is to be a trusted partner, delivering exceptional service and personalized solutions to meet your specific needs. Together, we are committed to advancing the next generation of RNA and protein therapeutics and vaccines, shaping the future of medicine one breakthrough at a time.


Meet Our Team

DarrickC-300x300

Darrick Carter, Ph.D.

Dr. Darrick Carter, Scientific Advisor, is a biochemist/biophysicist with over 20 years of biotechnology experience most recently serving as CSO of HDT Bio and VP of Adjuvant Technologies at AAHI (Formerly IDRI). He has founded five companies beginning with an internet startup. At Corixa he led a new tuberculosis vaccine into human trials. He started PAI as a bioinformatics company using proprietary artificial neural nets. He helped spin out Dharma Therapeutics a specialty pharma company for drug delivery. Next, he co-founded a company improving cancer outcomes, Compliment Corp. He is an inventor on over 120 patents and applications with more than 100 publications.

SeanGray

Sean Gray, Ph.D.

JennDavis

Jenn Davis, M.T., C.L.S.

Institutional Biosafety Committee (IBC)

On behalf of the institution, IBCs review research involving recombinant or synthetic nucleic acid molecules for compliance with the NIH Guidelines.